News & Publications

NEWS & PUBLICATIONS

Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

California Institute for Biomedical Research joins group of leading organizations using Prous Institute Symmetry

2015 Sep 23 |

Barcelona. Prous Institute announced today the deployment of its predictive analytics platform, Symmetry, at the California Institute for Biomedical Research (Calibr). Under the terms of the agreement, Calibr will employ the new resource in its translational research activities, leveraging Symmetry’s Global Mechanism of Action (GMoA) model for hypothesis generation in drug design and to support the assessment of on- and off-target activities.

Symmetry GMoA elucidates the probable molecular targets and mode of action of small molecules in a single predictive model. The model is trained with an up-to-date, expertly curated data set of >1 million compounds covering 850 mechanisms of action, derived from the analysis and selection from patents, journal articles and data from research collaborations and commercial partnerships.

Symmetry GMoA uses a proprietary multi-label learning algorithm that allows easy screening of chemical libraries. A ranked list of potential mechanisms of actions for each test structure is provided, along with the closest training set analogs and reference source information to support the interpretability of results.

Dr. Josep Prous, Jr., Vice President of Research and Development of Prous Institute, added "We are pleased to support Calibr's efforts to find better and safer drugs across a range of disease areas through the use of our technologies".

About California Institute for Biomedical Research

California Institute for Biomedical Research (Calibr, www.calibr.org), is an independent non-profit institute established in 2012 with the goal of accelerating the translation of basic research to new medicines that address unmet medical needs.  Calibr’s research interests span a large range of human diseases, including cancer, autoimmunity and inflammatory diseases, metabolic and cardiovascular diseases, infectious and neglected diseases, as well as age-related and degenerative diseases. Calibr receives support from foundations, federal and state government, and pharmaceutical industry partners.

About Prous Institute for Biomedical Research

Prous Institute for Biomedical Research is a privately-held research organization. It was founded as a spin-off of Prous Science, the leading scientific information provider (producer of Drugs of the Future, Drug Data Report and the Integrity drug discovery and development portal, amongst others) acquired by Thomson Reuters in 2007. Building on over 50 years of experience creating and managing biomedical knowledge, Prous Institute for Biomedical Research has developed Symmetry, an innovative predictive analytics platform to elucidate the efficacy and safety profile of new molecular entities. The platform helps to de-risk and prioritize projects and assays and speed up drug discovery and development, reducing time, costs and attrition rates. Symmetry applies advanced machine learning techniques to a variety of structural features and physicochemical properties of small molecules to provide quality predictions of biological effects.